Literature DB >> 12225376

Immunity to asexual blood stage malaria and vaccine approaches.

Jiraprapa Wipasa1, Salenna Elliott, Huji Xu, Michael F Good.   

Abstract

The development of a malaria vaccine seems to be a definite possibility despite the fact that even individuals with a life time of endemic exposure do not develop sterile immunity. An effective malaria vaccine would be invaluable in preventing malaria-associated deaths in endemic areas, especially amongst children less than 5 years of age and pregnant women. This review discusses our current understanding of immunity against the asexual blood stage of malaria - the stage that is responsible for the symptoms of the disease - and approaches to the design of an asexual blood stage vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225376     DOI: 10.1046/j.1440-1711.2002.01107.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  45 in total

1.  Immune responses of NIH mice infected with avirulent and virulent strains of Plasmodium chabaudi adami single and mixed infections.

Authors:  M J Namazi; R S Phillips
Journal:  Korean J Parasitol       Date:  2010-03-18       Impact factor: 1.341

2.  Immunophenotyping of blood mononuclear cells from P. berghei (NK-65) infected and immunized BALB/c mice.

Authors:  Vineet Kumar; Aruna Rakha; Ruchika Saroa; Upma Bagai
Journal:  J Parasit Dis       Date:  2016-06-03

Review 3.  Turf wars: exploring splenomegaly in sickle cell disease in malaria-endemic regions.

Authors:  Venée N Tubman; Julie Makani
Journal:  Br J Haematol       Date:  2017-05-11       Impact factor: 6.998

4.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax.

Authors:  Jiraprapa Wipasa; Chaisuree Suphavilai; Lucy C Okell; Jackie Cook; Patrick H Corran; Kanitta Thaikla; Witaya Liewsaree; Eleanor M Riley; Julius Clemence R Hafalla
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

6.  Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.

Authors:  Enmoore Lin; Benson Kiniboro; Laurie Gray; Stuart Dobbie; Leanne Robinson; Annemarie Laumaea; Sonja Schöpflin; Danielle Stanisic; Inoni Betuela; Melinda Blood-Zikursh; Peter Siba; Ingrid Felger; Louis Schofield; Peter Zimmerman; Ivo Mueller
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

7.  Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits.

Authors:  Kwadwo A Kusi; Bart W Faber; Marjolein van der Eijk; Alan W Thomas; Clemens H M Kocken; Edmond J Remarque
Journal:  Malar J       Date:  2011-02-14       Impact factor: 2.979

8.  Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity.

Authors:  Kristina E M Persson; Freya J I Fowkes; Fiona J McCallum; Nimmo Gicheru; Linda Reiling; Jack S Richards; Danny W Wilson; Sash Lopaticki; Alan F Cowman; Kevin Marsh; James G Beeson
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

9.  Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.

Authors:  A Rainczuk; T Scorza; P M Smooker; T W Spithill
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1.

Authors:  G Li; S H Basagoudanavar; D C Gowda
Journal:  Parasite Immunol       Date:  2008-04-14       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.